ADAM, Zdeněk, Jiří MAYER and Roman HÁJEK. Cisplatina a karboplatina při léčbě maligních lymfomů a mnohočetného myelomu (Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma). Vnitřní lékařství. Praha: Česk lékařská společnost J. Ev. Purkyně, 1994, vol. 40, No 12, p. 790-800. ISSN 0042-773X.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Cisplatina a karboplatina při léčbě maligních lymfomů a mnohočetného myelomu
Name (in English) Cisplatin and carboplatin in the treatment of malignant lymphoma and multiple myeloma
Authors ADAM, Zdeněk (203 Czech Republic), Jiří MAYER (203 Czech Republic, guarantor) and Roman HÁJEK (203 Czech Republic).
Edition Vnitřní lékařství, Praha, Česk lékařská společnost J. Ev. Purkyně, 1994, 0042-773X.
Other information
Original language Czech
Type of outcome Article in a journal
Field of Study 30200 3.2 Clinical medicine
Country of publisher Czech Republic
Confidentiality degree is not subject to a state or trade secret
Organization unit Faculty of Medicine
Keywords (in Czech) cisplatina; lymfom; mnohočetný myelom
Keywords in English cisplatin;carboplatin;lymphoma; multiple myeloma
Tags Carboplatin, cisplatin, Lymphoma, multiple myeloma
Changed by Changed by: Mgr. Anna Potáčová, Ph.D., učo 44190. Changed: 24/6/2009 10:39.
Abstract
Toto review shrnuje poznatky o užívání cisplatiny přo léčbě mnohočetného myelomu a zhoubných lymfomů.
Abstract (in English)
Experiences with cisplatin and carboplatin are summarized in this paper. The treatment response to monotherapy with cisplatin or carboplatin was proved in non-Hodgkin's lymphomas. This is necessary condition for the application of the drug in polychemotherapy. Cisplatin and carboplatin based combinations are not used as an initial therapy. The indications for these two drugs are primary resistant malignant lymphoma and multiple myeloma, or relapses of these diseases not responding to conventional therapy. Cisplatin based combination therapy can in these indications prolong the survival in 30-40% of patients. The role of carboplatin in malignant lymphoma is not clear yet and is under investigation. The effective antiemetic therapy (ondansetron, granisetron) miligated the fear of vomiting and therefore these combinations are used in resistant malignant lymphoproliferative diseases more then some years ago. In the tables are shown the chemotherapeutic combinations used in non-Hodgkin's lymphomas, Hodgkin disease and multiple myeloma.
PrintDisplayed: 24/4/2024 23:57